Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | CFO AND TREASURER | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,876 |
Ending reported balance
After 2026-06-22 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 8,750 · Balance 27,626 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Row 2 · 2026-06-22 · Sale · Disposed 164 · Balance 27,462 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-06-22 · Sale · Disposed 865 · Balance 26,597 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-06-22 · Sale · Disposed 1,091 · Balance 25,506 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-06-22 · Sale · Disposed 840 · Balance 24,666 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-06-22 · Sale · Disposed 2,266 · Balance 22,400 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-06-22 · Sale · Disposed 1,994 · Balance 20,406 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-06-22 · Sale · Disposed 280 · Balance 20,126 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-06-22 · Sale · Disposed 1,250 · Balance 18,876 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-22 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 506 | $534.60 | $270,506.18 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 16 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,476 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F16 · price: This transaction was executed in multiple trades at prices ranging from $534.12 to $535.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 642 | $533.60 | $342,568.57 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 15 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,982 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $533.09 to $534.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 288 | $532.59 | $153,387.27 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 14 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,624 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $532.09 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 587 | $531.49 | $311,984.86 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 13 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,912 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $531.08 to $532.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 577 | $530.64 | $306,177.32 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,499 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $530.05 to $530.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,620 | $529.04 | $1,386,092.66 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,076 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $529.02 to $530.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 80 | $527.49 | $42,199.45 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,696 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $527.13 to $528.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 520 | $526.57 | $273,817.75 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,776 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $526.09 to $526.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 320 | $525.37 | $168,118.40 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,296 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $524.98 to $525.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 440 | $524.20 | $230,648.04 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,616 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $523.85 to $524.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $522.36 | $104,472.90 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,056 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $522.04 to $522.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 905 | $521.47 | $471,926.91 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,256 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $520.99 to $521.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 875 | $520.62 | $455,539.35 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,161 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $519.98 to $520.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 640 | $519.30 | $332,353.60 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,036 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $518.89 to $519.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $518.28 | $103,656.60 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,676 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $517.82 to $518.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $135.42 | $1,354,200.00 |
DisclosureSEC source: 0001636178-26-000003 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 9,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · derivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F4 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 10,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · derivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F4 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Tax withholdingCommon Stock | 4,104 | $536.12 | $2,200,236.48 |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,876 F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Tax withholdingCommon Stock | 4,682 | $536.12 | $2,510,113.84 |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,980 F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 9,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · balance_after: Includes 42 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 3,517 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,517 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 241 | $500.30 | $120,573.02 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,142 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $499.92 to $500.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 240 | $499.31 | $119,835.17 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,383 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $498.88 to $499.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 395 | $498.09 | $196,745.04 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,623 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $497.60 to $498.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $496.97 | $99,394.80 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,018 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $496.59 to $497.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 520 | $495.90 | $257,868.83 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,218 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $495.52 to $496.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 360 | $495.02 | $178,205.72 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,738 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $494.52 to $495.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 561 | $493.70 | $276,968.06 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,098 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $493.35 to $494.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 840 | $492.81 | $413,957.96 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,659 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 160 | $491.53 | $78,644.00 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,499 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $491.19 to $491.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,517 | $146.03 | $513,587.51 |
DisclosureSEC source: 0001636178-25-000010 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F2 · balance_after: The amount of common stock beneficially owned by the Reporting Person in the Reporting Person's Form 4s filed November 5, 12 and 18, 2025 did not include 24 shares acquired by the Reporting Person on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan, which error caused the reporting person's common stock ownership to be underreported by 24 shares on such Form 4s. The amount of common stock beneficially owned by the Reporting Person in this Form 4 includes such shares. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 21,000 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · derivative · entry 14 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,517 Underlying: Common Stock · 21,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 520 | $486.71 | $253,089.62 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 13 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,142 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $486.68 to $486.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $484.85 | $58,181.60 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,662 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $484.83 to $484.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 739 | $484.51 | $358,052.52 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,782 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $483.76 to $484.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 742 | $483.29 | $358,598.51 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,521 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $482.76 to $483.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 523 | $482.22 | $252,199.02 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,263 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $481.70 to $482.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 477 | $481.22 | $229,544.09 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,786 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $480.68 to $481.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,559 | $480.03 | $748,368.80 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,263 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $479.65 to $480.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,139 | $479.16 | $1,504,073.82 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,822 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $478.63 to $479.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,295 | $477.97 | $1,574,906.87 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,961 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $477.60 to $478.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,529 | $477.18 | $3,115,502.34 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,256 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $476.60 to $477.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,957 | $476.17 | $1,408,045.93 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,785 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $475.60 to $476.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $475.08 | $190,033.92 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,742 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $474.57 to $475.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 21,000 | $146.03 | $3,066,630.00 |
DisclosureSEC source: 0001636178-25-000009 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 20,483 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001636178-25-000008 · primarydocument.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,517 Underlying: Common Stock · 20,483 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 517 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001636178-25-000008 · primarydocument.xml · derivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 517 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 160 | $484.68 | $77,548.80 |
DisclosureSEC source: 0001636178-25-000008 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,142 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.